Case 3: Critical Issues

Critical issues

– Inhibitors are allo-antibodies against factor VIII

– Complicate the treatment of 20 to 30% of patients with severe hemophilia A¹

– Commonly develop in patients aged 1 to 2 years²

– Inhibitor development typically occurs early during treatment, on average before the 15th, and almost always before the 50th, infusion of FVIII³

– Occur after an average of 10 to 20 days of treatment in 73% of patients²

– Inhibitors can render FVIII replacement therapy ineffective, resulting in increased

• Disease-related morbidity
• Product utilization
• Hospitalization

1. Kruse-Jarres R. Haemophilia. 2013;19(Suppl. 1):2-7.
2. Hay CR. Haemophilia. 2006;12(Suppl 6): 23-29.
3. Astermark J. Haemophilia. 2006; 12(Suppl. 3): 52–60.